X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (200) 200
hematology (155) 155
male (141) 141
index medicus (136) 136
female (135) 135
middle aged (134) 134
adult (125) 125
aged (106) 106
oncology (95) 95
adolescent (58) 58
aged, 80 and over (49) 49
cancer (42) 42
prognosis (39) 39
leukemia (36) 36
treatment outcome (36) 36
young adult (33) 33
chemotherapy (32) 32
hemic and lymphatic diseases (31) 31
retrospective studies (31) 31
therapy (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
expression (26) 26
mutation (26) 26
chronic myelogenous leukemia (25) 25
survival analysis (25) 25
analysis (24) 24
in situ hybridization, fluorescence (24) 24
translocation, genetic (24) 24
antineoplastic agents - therapeutic use (22) 22
chronic myeloid leukemia (22) 22
lymphomas (21) 21
medicine & public health (21) 21
hematology, oncology and palliative medicine (20) 20
leukemia, myeloid, acute - genetics (20) 20
survival (20) 20
classification (19) 19
genetic aspects (18) 18
leukemia, myelogenous, chronic, bcr-abl positive - genetics (18) 18
risk factors (18) 18
acute myeloid leukemia (17) 17
disease (17) 17
transplantation (17) 17
abridged index medicus (16) 16
care and treatment (16) 16
mutations (16) 16
acute myeloid-leukemia (15) 15
follow-up studies (15) 15
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (15) 15
remission induction (15) 15
research (15) 15
acute disease (14) 14
acute myelogenous leukemia (14) 14
acute promyelocytic leukemia (14) 14
benzamides (14) 14
child (14) 14
fusion proteins, bcr-abl - genetics (14) 14
gene expression (14) 14
imatinib mesylate (14) 14
prospective studies (14) 14
survival rate (14) 14
t (14) 14
bone marrow (13) 13
disease-free survival (13) 13
gene (13) 13
genetics & heredity (13) 13
oncogene proteins, fusion - genetics (13) 13
stem cells (13) 13
chromosome deletion (12) 12
genes (12) 12
imatinib (12) 12
leukemia, promyelocytic, acute - genetics (12) 12
myelodysplastic syndromes (12) 12
pyrimidines - therapeutic use (12) 12
risk (12) 12
age factors (11) 11
diagnosis (11) 11
further section (11) 11
karyotyping (11) 11
leukemia, myeloid, acute - drug therapy (11) 11
lymphoma (11) 11
pathology (11) 11
philadelphia chromosome (11) 11
time factors (11) 11
transplantation of organs, tissues, etc (11) 11
animals (10) 10
chromosome aberrations (10) 10
chronic myeloid-leukemia (10) 10
cytogenetic analysis (10) 10
cytogenetics (10) 10
dasatinib (10) 10
fish (10) 10
flow cytometry (10) 10
management (10) 10
polymerase chain reaction (10) 10
precursor cell lymphoblastic leukemia-lymphoma - genetics (10) 10
recurrence (10) 10
remission (10) 10
reverse transcriptase polymerase chain reaction (10) 10
acute lymphoblastic-leukemia (9) 9
aml (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 111 - 121
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 22 - 33
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease
Journal Article
Clinical Management Issues, ISSN 1973-4832, 10/2015, Volume 7, Issue 1S, pp. 3 - 7
Journal Article
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, ISSN 1422-0067, 06/2019, Volume 20, Issue 12, p. 2929
Journal Article
Haematologica, ISSN 0390-6078, 04/2010, Volume 95, Issue 4, pp. 644 - 650
Journal Article
Frontiers in Immunology, ISSN 1664-3224, 10/2018, Volume 9, p. 2459
We have previously shown that through the production of high LIGHT levels, immune cells contribute to both osteoclastogenesis and bone destruction in Multiple... 
monocytes | RANKL | Multiple myeloma | CD16 | Bone disease | CD14 | LIGHT/TNFSF14 | CELLS | multiple myeloma | ACTIVATION | OSTEOCLASTS | LIGHT | TUMOR | IMMUNOLOGY | PATHOGENESIS | DESTRUCTION | HERPESVIRUS ENTRY MEDIATOR | SUPERFAMILY | CD14(+)/CD16(+) monocytes | EXPRESSION | bone disease | Care and treatment | Usage | Bone diseases | Research | Biological markers | CD14+/CD16+ monocytes
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 3, pp. 219 - 228
Journal Article